MAPT and supranuclear palsy, progressive, 1: Our work is the first study, to our knowledge, demonstrating a blood-based, and therefore low invasive and easily accessible, fluid biomarker, which has great potential as a diagnostic marker to distinguish FTLD-TDP from FTLD-tau, and to detect ALS and PSP.